Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

AIDS

Volumn 23, Issue 11, 2009, Pages 1383-1388

  Viard, Jean Paul ^a   Fagard, Catherine ^b   Chaix, Marie Laure ^a   Rouzioux, Christine ^a   Bouteloup, Vincent ^b   Bentata, Michelle ^c   De Verdière, Nathalie Colin ^d   Pahlavan, Golriz ^e   Weiss, Laurence ^f   Lévy, Yves ^g   Chêne, Geneviève ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c AVICENNE HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g HENRI MONDOR HOSPITAL   (France)

Author keywords

Enfuvirtide; HIV; Interleukin 2; Randomized trial; Treatment failure

Indexed keywords

ENFUVIRTIDE; INTERLEUKIN 2; RITONAVIR PLUS TIPRANAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT FAILURE; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGIC METHODS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RNA, VIRAL; TREATMENT FAILURE;

EID: 68449098785     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832cdc26     Document Type: Article

References (27)

1. Lévy Y. Cytokine-based modulation of immune function in HIV infection. Curr Opin HIV AIDS 2006; 1:69-73.
2. Carcelain G, Saint-Mézard P, Altes HK, Tubiana R, Grenot P, Rabian C, et al. IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients wit severe CD4 lympho-penia. AIDS 2003; 17:841-850.
3. Natarajan V, Lempicki RA, Sereti I, Badralmaa Y, Adelsberger JW, Metcalf JA, et al. Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci U S A 2002; 99:10712-10717.
4. Kovacs J, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115:2139-2148.
5. Lévy Y, Capitant C, Houhou S, Carrière I, Viard JP, Goujard C, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomized trial. Lancet 1999; 353:1923-1929.
6. Gougeon ML, Rouzioux C, Liberman I, Burgard M, Taoufik Y, Viard JP, et al. Immunological and virological effects of long-term IL-2 therapy in HIV-infected patients. AIDS 2001; 15:1729-1731.
7. Lévy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomised controlled trial. AIDS 2003; 17:343-352.
8. Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, et al. Long-terme effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048+-079 trials). AIDS 2007; 21:1887-1897.
9. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahay J, Reich-man R, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection. Arch Intern Med 2007; 167:597-605.
10. Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <250/microL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999; 180:56-60.
11. David D, Naït-lghil L, Dupont B, Maral J, Gachot B, Thèze J. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected persons whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis 2001; 183:730-735.
12. Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002; 186: 606-616.
13. Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS 2002; 16:2027-2034.
14. Markowitz N, Bebchuk JD, Abrams Dl. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. Clin Infect Dis 2003; 37:e115-e120.
15. Youle M, Emery S, Fisher M, Nelson M, Fosdick L, Janossy G, et al. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard study. PloS Clin Trials 2006; 1:e3; doi: 10.1371/journal.pctr.0010003.
16. Herzman C, Cuthbertson Z, Fosdick L, Fisher, Nelson M, Perry N, et al. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2008; 62:583-586.
17. Molina JM, Lévy Y, Fournier I, Boulet T, Bentata M, Beck-Wirth G, et al. Predictors of slow disease progression in ART-naïve HIV-1-infected patients treated with IL-2:3 year extended follow-up of the INTERSTART ANRS 119 trial [abstract #702]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts; 2008.
18. Sereti I, Sklar P, Ramchandani S, Read SW, Aggarwal V, Imamichi H, et al. CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis 2007; 196: 677-683.
19. ESPRIT Research Group. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >300 cells/μI who were assigned to 7.5 MIU interleukin-2. HIV Med 2007; 8:112-23.
20. 3: primary results of the SILCAAT study [abstract #90bLB]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada; 2009.
21. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. I Clin Pathol 2007;60:1365-1372.
22. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, et al. Interleukin-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patient, results from FHDH ANRS CO4. J Acquir Immune Defic Syndr 2009; 50:206-214.
23. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
24. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of Enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
25. Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, et al. Specific enfuvirtide-associated mutational pathways in HIV-1 gp 41 are significantly correlated with an increase in CD4+ cell count, despite virological failure. J Infect Dis 2008; 197:1408-1418.
26. Barretina J, Blanco J, Armand-Ugón M, Gutiérrez A, Clotet B, Esté JA. Anti-HIV-1 activity of enfuvirtide (T20) by inhibition of bystander cell death. Antivir Ther 2003; 8:156-161.
27. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Esté JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18:1673-1682.